Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis.

Gupta T. et al, (2024), Cancer Cell, 42, 797 - 814.e15

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.

Wong S-Y. et al, (2023), Inflamm Bowel Dis, 29, 1693 - 1705

HIGHLY STABLE EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION SIGNATURES ACCURATELY PREDICT RESPONSE TO ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

Joustra V. et al, (2023), GUT, 72, A36 - A38

Pathogenesis of fistulating Crohn's disease: a review.

Chantelle McGregor CG. et al, (2022), Cell Mol Gastroenterol Hepatol

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.

Adams A. et al, (2022), Gut

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.

Wellens J. et al, (2022), Gut, 71, 1919 - 1922

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

McGregor CG. et al, (2021), Gut, 70, 2398 - 2400

REAL WORLD EFFECTIVENESS OF USTEKINUMAB FOR REFRACTORY CROHN'S DISEASE: A REGIONAL EXPERIENCE

Mcgregor C. et al, (2021), GUT, 70, A108 - A108